Biogen (BIIB) Pullback Post FDA Approval Provides Buying Opportunity - Jefferies
Tweet Send to a Friend
Jefferies analyst Michael Yee reiterated a Buy rating and $500.00 price target on Biogen (NASDAQ: BIIB) noting shares have traded ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
